NAD Peptide Research MOTS-c: What the Data Shows

Two of the three compounds in a NAD peptide research MOTS-c blend are not peptides. NAD+ is a 663-dalton dinucleotide coenzyme, and 5-Amino-1MQ is a small-molecule enzyme inhibitor. Only MOTS-c fits the definition.

Our team fields procurement questions about these blends constantly, and the pattern never changes: researchers ask about milligram strength long before they ask what fraction of that milligram figure belongs to each compound.

What is a NAD peptide research MOTS-c blend?

A NAD peptide research MOTS-c blend is a single research vial containing NAD+, the mitochondrial-derived peptide MOTS-c, and the NNMT inhibitor 5-Amino-1MQ, usually labeled by total mass such as 150mg or 300mg. That total says nothing about the per-compound split, which only a certificate of analysis can confirm.

The over-simplification worth correcting early: these blends are not a formulation validated as a combination. Each compound carries its own literature, and the trio carries almost none. What follows covers the NAD+ salvage pathway logic that connects them, how the 150mg and 300mg labels are actually constructed, and why a research supplier publishes concentration math instead of dosage.

Three molecular classes in one research vial

A NAD peptide research MOTS-c blend combines a coenzyme, a peptide, and a small molecule, which is an unusual thing to find in one lyophilized vial. NAD+ (nicotinamide adenine dinucleotide) is a 663-dalton dinucleotide that shuttles electrons between glycolysis, the TCA cycle, and oxidative phosphorylation. It is also consumed as a substrate by the sirtuins (SIRT1 through SIRT7, a family of NAD+-dependent deacylases), by PARPs (poly ADP-ribose polymerases, which repair DNA strand breaks), and by the ecto-enzyme CD38. There are no amino acids in it anywhere.

MOTS-c is the only genuine peptide present. The name stands for mitochondrial open reading frame of the 12S rRNA type-c, and it is a 16-amino-acid sequence (MRWQEMGYIFYPRKLR) encoded inside the mitochondrial genome rather than the nuclear one. Work published by Lee and colleagues in Cell Metabolism in 2015 described MOTS-c acting on the folate-methionine cycle, with downstream AICAR accumulation and AMPK activation in rodent models. A 2021 Nature Communications paper from Reynolds and colleagues reported MOTS-c behaving as an exercise-responsive regulator in skeletal muscle.

5-Amino-1MQ (5-amino-1-methylquinolinium) is the third and smallest component, a membrane-permeable small molecule roughly a tenth the mass of MOTS-c. Studies describe it as an inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme with no obvious link to the other two until you follow where nicotinamide goes.

Most confusion in this category starts with one assumption: that everything inside a peptide vial is a peptide.

The NNMT bottleneck that links all three compounds

The pathway rationale behind NAD peptide research MOTS-c blends runs through the salvage pathway, which is how most mammalian cells regenerate NAD+. Nicotinamide is converted to NMN (nicotinamide mononucleotide) by NAMPT, the rate-limiting enzyme, then to NAD+ by the NMNAT enzymes. NNMT competes for that same nicotinamide pool. It transfers a methyl group from SAM (S-adenosylmethionine) onto nicotinamide, producing 1-methylnicotinamide and permanently removing that molecule from salvage. Inhibit NNMT and more nicotinamide stays in play. Neelakantan and colleagues reported in Biochemical Pharmacology in 2018 that membrane-permeable small-molecule NNMT inhibitors reduced adiposity in diet-induced obese mice.

MOTS-c enters from the energy-sensing side through AMPK, which the literature describes in a reciprocal relationship with NAD+ and SIRT1. The blend logic, stated plainly: supply the cofactor, block the methylation drain, activate the sensor.

Here is the wrinkle most blend descriptions skip entirely. NAD+ does not cross the plasma membrane intact in any meaningful quantity. Research describes extracellular NAD+ being degraded by ecto-enzymes including CD38 and CD73 into nicotinamide riboside and nicotinamide, which are then imported and re-phosphorylated inside the cell. The practical consequence is significant: the NAD+ milligrams in the vial largely reach cells as precursors rather than as the finished coenzyme, which makes the NNMT inhibitor arguably a more interesting variable than the compound the blend is named after.

We are not aware of any published controlled study evaluating these three compounds delivered as a single combination. The trio is a hypothesis, not a finding.

Reading a NAD peptide research MOTS-c blend label

The searches that bring people here are strength searches: 150mg blends, 300mg blends, and the split hiding behind those totals. That figure is the sum of all three components, so two vials carrying the same total mass can contain completely different ratios of NAD+ to MOTS-c to 5-Amino-1MQ. The ratio is the experimentally meaningful number. The total is packaging.

A certificate of analysis for a three-component blend should carry three identity confirmations, not one. These compounds do not share an analytical method. Peptides like MOTS-c are characterized by reverse-phase HPLC with mass spectrometry confirming the expected molecular ion, NAD+ carries its own UV absorbance signature near 260nm from the adenine ring, and 5-Amino-1MQ behaves as a small quinolinium salt with different chromatographic properties again. A single chromatogram for a blend proves one peak eluted cleanly. It proves nothing about the other two.

On dosage, we will be direct. Real Peptides does not publish dosing, preparation, or administration guidance for any catalog compound, including NAD+ / MOTS-c / 5-Amino-1MQ blends. These are research-use-only materials that are not approved as drugs, so no dosage exists for them in any regulatory sense. The only quantitative framework that belongs in supplier documentation is concentration arithmetic: total milligrams per milliliter of solution, and, where the certificate discloses the split, milligrams per milliliter of each individual component. Study parameters belong in published protocols written by the investigators running them.

How the three components differ on the bench

These three compounds share a vial but almost nothing else. The table below sets out what separates them analytically, mechanistically, and in terms of what a buyer should demand on paper.

What If: Blend Sourcing and Handling Scenarios

What if my vial only lists a total of 150mg?

Request the per-component breakdown in writing before the material enters any study design. A 150mg total is a sum, and without the split you cannot calculate the concentration of any individual compound, which makes the resulting data uninterpretable by anyone reviewing it later. Suppliers who synthesize and fill their own blends can produce that breakdown immediately. Suppliers who cannot are usually reselling a pre-mixed product they did not formulate.

What if the certificate of analysis shows one chromatogram for the whole blend?

Treat it as evidence for one component rather than three, and ask for the remaining assays. NAD+, MOTS-c and 5-Amino-1MQ do not respond to a single analytical method in a way that allows simultaneous quantification with confidence. A blend certificate should read like three documents stapled together, because that is essentially what an honest one is.

What if I need to know how much of the blend to use?

That question has no supplier-side answer, and any vendor offering one is telling you something about their compliance posture rather than your experiment. Research-use-only compounds have no established dosage because they are not approved as drugs for any species. The framework that does belong in your notes is concentration: total milligrams per milliliter, and per-component milligrams per milliliter where the certificate discloses the ratio.

What if the lyophilized cake looks shrunken, discolored, or partially collapsed?

Quarantine the vial, photograph it, and contact the supplier before doing anything else with it. Cake collapse typically indicates moisture ingress or a temperature excursion in transit, and NAD+ is hygroscopic enough that water uptake accelerates its degradation well before any visual change becomes obvious. Appearance is a crude signal in both directions: a normal-looking cake does not confirm potency, and an abnormal one is a hard stop.

The awkward truth about three-compound research blends

Let's be direct about this: a three-compound blend is a convenience product, not an experimental design. If a model shows a change, you cannot attribute it to NAD+, to MOTS-c, or to 5-Amino-1MQ, because all three moved simultaneously and none moved independently. Reviewers know this, which is why anyone planning to publish ends up buying single-compound vials to run the arms separately. Blends earn their place in exactly one situation: exploratory screening, where the question is whether anything happens at all before committing to a factorial design. That is a legitimate use. It is also a much narrower one than the category suggests.

Researchers who prefer to move one variable at a time can source the components individually, since MOTS-c, 5-Amino-1MQ and NAD+ 100mg are all supplied as single-compound research material with published certificates of analysis, alongside background pages covering the NAD+ pathway and MOTS-c literature and the wider research catalog.

The NAD peptide research MOTS-c category is a decent test of how a supplier thinks. Three molecules from three different chemical families, filled into one vial, described by a single number that sums them without characterizing any of them. The compounds are genuinely interesting and the salvage-pathway logic connecting them is real science worth following. The label is not science. Ask for the split, ask for three separate assays, and the blend stops being a black box and starts being something you can actually reason about.